Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      ACE Study Group
    • Source:
      Publisher: Mosby Country of Publication: United States NLM ID: 0370465 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6744 (Electronic) Linking ISSN: 00028703 NLM ISO Abbreviation: Am Heart J Subsets: MEDLINE
    • Publication Information:
      Original Publication: St. Louis, MO : Mosby
    • Subject Terms:
      Acarbose/*therapeutic use ; Blood Glucose/*metabolism ; Coronary Disease/*prevention & control ; Diabetes Mellitus, Type 2/*prevention & control ; Glucose Intolerance/*drug therapy ; Secondary Prevention/*methods; Blood Glucose/drug effects ; Coronary Disease/blood ; Coronary Disease/complications ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/complications ; Disease Progression ; Double-Blind Method ; Follow-Up Studies ; Glucose Intolerance/blood ; Glucose Intolerance/complications ; Humans ; Hypoglycemic Agents/therapeutic use ; Prospective Studies ; Treatment Outcome
    • Abstract:
      Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.
      (Copyright © 2014 Mosby, Inc. All rights reserved.)
    • Contributed Indexing:
      Investigator: RR Holman; CY Pan; D Hu; J Chan; JL Chiasson; Z Doran; J Ge; H Gerstein; Y Huo; Z Lang; J McMurray; L Ryden; S Schröder; M Tendera; J Tuomilehto; W Yang; J Rouleau; J Collier; S Pocock; E Standl; K Swedberg; J Weng; D Zhao; D Wang; M Petrie; E Connelly; P Jhund; M MacDonald; R Myles; N Sattar; M Fisher; J Petrie; Y Sun; Y Wei; W Xu; N Groves; W Liyanage; J Tang; MJ Theodorakis; J Bi; H Feng; R Hu; P Liu; M Wei; X Wei; X Yang; J Yin; J Zhou; L Deng; D Hu; Q Hua; T Hu; H Li; H Li; J Lu; C Ma; X Ma; L Pi; L Shi; B Wang; M Wang; G Wei; M Yang; W Yang; L Zhang; S Zhang; Y Zhou; H Lei; R Liao; X Mei; Q She; J Tan; M Xia; L Chen; X Pu; Y Wang; Q Xie; S Xiong; C Chen; J Chen; Y Dong; Z Li; C Wu; S Zhou; Y Yuan; W Zhou; R Kuang; J Wei; Z Zhao; G Zhong; L Wu; H Fang; H Li; L Kong; G Liu; Y Hao; C Wang; X Li; L Wang; P Dong; H Liu; X Liu; S Zhang; Y Zhao; J Chan; R Ozaki; Y Gu; Y Liao; X Su; D Wang; H Wang; B Yang; Y Guo; T Yang; Y Han; X Lin; R Zhao; R Bian; Y Guo; H Zhang; B Hasimu; H Jin; P Liu; K Lv; Y Tao; C Xu; B Xu; Z Yang; J Yu; G Zhang; L Hong; L Hu; J Li; B Liu; P Yang; P Han; Y Jin; L Li; H Lin; J Liu; Z Li; G Wang; S Zhang; H Luan; M Song; L Xue; J Feng; F Gao; Y Hua; J Ye; Z Yuan; Z Hou; X Li; W Qi; G Su; Y Wang; S Zhang; B Wang; J Ge; X Guo; H Gong; S Gu; B He; Y Jiang; H Jin; Y Li; Q Liu; G Lu; J Ma; Y Qin; S Wu; Y Xu; X Chen; J Tang; J Wang; D Liu; X Chen; J Tao; Y Yan; T Zhang; D Li; X Du; X Guo; T Jiang; T Li; Z Li; J Lin; C Lu; S Zhao; S Zheng; K Li; Q Qui; B Tang; J Zhou; G Zhang; T Guo; H Zhang; F Shen; G Fu
    • Accession Number:
      0 (Blood Glucose)
      0 (Hypoglycemic Agents)
      T58MSI464G (Acarbose)
    • Publication Date:
      Date Created: 20140623 Date Completed: 20140902 Latest Revision: 20140623
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.ahj.2014.03.021
    • Accession Number:
      24952856